View Older Stories View More Recent Stories
-
Strongbridge Biopharma plc Announces Pricing of Its Initial U.S. Public Offering
-
Strongbridge Biopharma plc Announces Pricing of Its Initial U.S. Public Offering
-
Roth Capital Reiterates Buy on Sarepta Therapeutics (SRPT) as Advisory Meeting Set for January 22nd
-
ROTH Capital Partners to Host Gene Therapy Corporate Access Day in New York on October 27th, 2015
-
Roth Capital Starts Horizon Global Corp. (HZN) at Buy
-
Roth Capital Cuts Price Target on Intel (INTC) Following 3Q Earnings Results
-
Take it One Month at a Time: LiquidSpace Launches Monthly Rentals, New Legal Framework
-
Hannon Armstrong (HASI) Prices 5M Common Stock Offering at $18/Share
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces the Pricing of its Public Offering of Common Stock
-
Hannon Armstrong (HASI) Commences 5M Share Common Stock Offering
-
Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces Public Offering of Common Stock
-
Roth Capital Reiterates Buy on Unique Fabricating (UFAB) Following Announced New Program Order
-
Roth Capital Reiterates Buy on Zosano Pharma (ZSAN) Following Positive ZP-Glucagon Data
-
ROTH Capital Partners Releases its 2015-2016 Millennial Mom Survey
-
Roth Capital Reiterates Buy on uniQure (QURE) Ahead of Analyst/R&D Day
-
Roth Capital Assumes NVIDIA (NVDA) at Neutral
-
Sarepta Therapeutics Announces Closing of $127 Million Public Offering of Common Stock
-
Roth Affirms AcelRx (ACRX) at 'Buy' Following Zalviso Update
-
Roth Capital Reiterates Buy on Concert Pharma (CNCE) Following a Milestone Achievement
-
Roth Capital Starts Immune Pharmaceuticals (IMNP) at Buy
-
Titan Pharmaceuticals Provides Opinion of Counsel Covering Issuance and Resale of Shares Underlying Public Warrants
-
SunEdison (SUNE) Business Update Positive for the Solar Sector - Roth Capital
-
Roth Capital Reiterates Buy on Così (COSI) Following Soft September Comps
-
PlacementTracker Publishes Third Quarter 2015 PIPE Market League Tables
-
Exact Sciences (EXAS) PT Lowered to $15 at Roth Capital, Recommends Buying on Weakness
-
UPDATE: Sarepta's (SRPT) Prices 3.25M Common Stock Secondary Offering at $39/Share
-
Sarepta Therapeutics Announces Pricing of $127 Million Public Offering of Common Stock
-
Streetinsider.com's Hot Lunchtime Reads 10/5: (AAPL) (ONCE) (TWTR) (BLUE)
-
Pioneer Announces Full Exercise of Underwriters' Over-Allotment Option
-
Roth Capital Raises Price Target on Spark Therapeutics (ONCE) to $90 Following Top-Line Results
-
Roth Capital Reiterates Buy on Hannon Armstrong (HASI) Following Investor Meetings
-
Roth Capital Reiterates Buy on Masimo Corp. (MASI) After Meeting with Management
-
Roth Capital Upgrades FutureFuel Corp. (FF) to Buy
-
Sarepta Therapeutic (SRPT) Data 'In-Line', Roth Capital Says
-
Roth Capital Cuts Price target on Energy Fuels (UUUU) Following Announced Upgrades
-
Pioneer Announces Closing of $4.5 Million Public Offering of Common Stock
-
Roth Capital Cuts Price Target on Yingli Green Energy (YGE) Following Announced Repayment Restructure
-
Roth Capital Cuts Price Target on Depomed (DEPO) as Horizon Pharma (HZNP) Trades Down
-
Roth Capital Raises Price Target on Ligand Pharma (LGND) Ahead of 3Q Results
-
Roth Capital Starts MaxLinear (MXL) at Buy
-
Roth Capital Cuts Price Target on Zosano Pharma (ZSAN) Following Announced Discontinuance of ZP-PTH Agreement
-
Roth Capital Re-Starts Cosi Inc. (COSI) at Buy
-
Roth Capital Boosts FY16 Ests on Ballard Power (BLDP) Following Wins in China; Affirms at 'Buy'
-
Roth Capital Starts Inuvo (INUV) at Buy
-
Streetinsider.com's Hot Lunchtime Reads 9/28: (BID) (GALE) (AAPL) (QSR)
-
Roth Capital Reiterates Buy on Rexahn Pharma (RNN) as Data Flows Begin
-
Rexahn Pharma (RNN) Starts Data Flow on RX-5902, RX-3117; Roth Capital Affirms at 'Buy'
-
Roth Affirms Galena Biopharma (GALE) at 'Buy' Fllowing GALE-301 Phase 2a Update; 1000 mcg Seen as Optimal
-
Roth Capital Downgrades Verastem (VSTM) to Neutral
-
Roth Capital Raised Price Target on VBL Therapeutics (VBLT) Following ASCO Showing

